Embecta said its patch pump would require additions to be commercially competitive, and plans to use the funds saved to pay down debt.
A London scientist is working on the world’s first oral insulin patch that could save diabetes patients from having to regularly inject the drug. Dr Hend Abdelhakim, an assistant professor at ...
The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...
Jury finds medical device company misappropriated secrets covering Insulet’s Omnipod l Insulet “extremely pleased” with ...
Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...
Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.
Embecta (Nasdaq:EMBC) filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees.
CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the ...
The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...
Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...
Embecta Corp.'s Q4 results showed significant net income and EPS growth. Embecta also announced a restructuring plan. See why ...
Insulet Corp., a Massachusetts-based medical device company, secured a staggering $452 million jury verdict against South ...